NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present a company update at the upcoming BIO International Convention, to be held June 13-16 in San Diego, CA.
Sam Zhang, Ph.D., MBA, NeoImmuneTech Chief Business Officer said: “One week after NeoImmuneTech presented new promising data at ASCO 2022 congress, the BIO International Convention is a perfect opportunity to remind the scientific and industry community about the momentum of our broad development program with NT-I7, our long-acting human IL-7, in combination with checkpoint inhibitors and CAR-Ts”.
The details of the company’s presentation are as follows:
BIO International Convention
Title: Expanding the Frontier of Immuno-Oncology with NT-I7, a long acting IL-7, in combination of checkpoint inhibitors and CAR-Ts
Date: Tuesday, June 14th, 2022
Time: 12:00 PM - 12:15 PM (PDT)
Where: Company Presentation Theater 4
Website: BIO International Convention
Media inquiries : firstname.lastname@example.org